{"id":"W2970734757","doi":"10.1158/1078-0432.ccr-18-4121","title":"Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":164,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; Genentech; Pharmacyclics; Eisai; National Institutes of Health; Cancer Research UK; Gilead Sciences; GlaxoSmithKline; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Nausea; Adverse effect; Pharmacokinetics; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Regimen; Progressive disease; Internal medicine; Dosing; Gastroenterology; Toxicity; Pharmacology; Chemotherapy; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006227496,0.0009347261,0.001148353,0.0002026082,0.0002130471,0.0004064193,0.000436732,0.0004864511,0.002363157],"category_scores_gemma":[0.0004059014,0.0003299485,0.0006212238,0.0002332112,0.0004390995,0.0003729358,0.0002056989,0.001556747,0.0005452192],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005396584,"about_ca_system_score_gemma":0.001119733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004203005,"about_ca_topic_score_gemma":0.001775507,"domain_scores_codex":[0.9998581,0.00005992066,0.000008881203,0.00002444268,0.00001974727,0.00002875016],"domain_scores_gemma":[0.9997047,0.00004231982,0.00008598379,0.0000181587,0.00002079177,0.0001281991],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4432971,0.04946663,0.0215326,0.00260653,0.002306467,0.0008449472,0.0005075794,0.008662604,0.2102123,0.0005606309,0.01086763,0.249135],"study_design_scores_gemma":[0.4432702,0.5029721,0.02687919,0.00008055134,0.0006188553,0.001344071,0.00008918628,0.002555741,0.01498619,0.0002775606,0.006888509,0.00003781787],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926406,0.002933729,0.0006562314,0.0002755265,0.00006259895,0.001231294,0.0006018259,0.00009972051,0.001498473],"genre_scores_gemma":[0.9926088,0.001861453,0.001286682,0.0003290671,0.00007234209,0.0009549881,0.001228169,0.00001740638,0.001641151],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002363157,"threshold_uncertainty_score":0.007905483,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05720851192970894,"score_gpt":0.4582961304115014,"score_spread":0.4010876184817924,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}